Neurosense Therapeutics Ltd banner
N

Neurosense Therapeutics Ltd
NASDAQ:NRSN

Watchlist Manager
Neurosense Therapeutics Ltd
NASDAQ:NRSN
Watchlist
Price: 0.8594 USD 1.11% Market Closed
Market Cap: $25.5m

Neurosense Therapeutics Ltd
Investor Relations

Neurosense Therapeutics Ltd. operates as a clinical stage drug development company. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Alon Ben-Noon
Co-Founder, CEO & Director
No Bio Available
Mr. Or Eisenberg
Chief Financial Officer
No Bio Available
Ms. Hagit Binder
Chief Operation Officer
No Bio Available
Dr. Niva Russek-Blum Ph.D.
Chief Technology Officer
No Bio Available
Dr. Ferenc Tracik M.D.
Chief Medical Officer
No Bio Available
Ms. Yael Barak
VP of Quality & Compliance
No Bio Available
Ms. Keren Pushett
Head of HR
No Bio Available
Mr. Eidan Loushi
C.R.A.
No Bio Available

Contacts

Address
Herzliya
11 Hamenofim St., Building B
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett